PMID- 10348149
OWN - NLM
STAT- MEDLINE
DCOM- 19990603
LR  - 20190921
IS  - 0939-5555 (Print)
IS  - 0939-5555 (Linking)
VI  - 78
IP  - 4
DP  - 1999 Apr
TI  - Generation of dendritic cells from patients with chronic myelogenous leukemia.
PG  - 181-6
AB  - Dendritic cells (DCs) are professional antigen-presenting cells (APCs) 
      specialized to internalize, process, and present antigen. They have the capacity 
      to stimulate the primary immune response of resting T-cells. We generated DCs 
      from the adherent cell fraction of peripheral blood, as well as from purified 
      CD34+ cells from CML patients. Characterizing DCs from ten CML patients by flow 
      cytometry, we found that these cells are highly positive for HLA-DR, CD1a, CD23, 
      and CD80 and negative for CD14, CD15, and CD16. The yield of DCs ranged from 19.5 
      to 68%. In addition, we used a functional test of FITC-dextran uptake to verify 
      that early DCs take up large particles (0.5-3 microm) by macropinocytosis while 
      monocytes do not. FITC-dextran uptake was detected by flow cytometry, showing 
      that DCs had accumulated these fluorescent particles. Electron-microscopic 
      analysis showed no major morphological differences between normal and CML-derived 
      DCs. Furthermore, cultured DCs were isolated by FAC sorting for CD1a and HLA-DR 
      expression. In these highly purified cells the Ph chromosome was detected by 
      interphase fluorescence in situ hybridization (FISH) and by fluorescence 
      immunophenotyping and interphase cytogenetics as a tool for the investigation of 
      neoplasms (FICTION); 30-85% of DCs generated were Ph-chromosome positive. It 
      might therefore be possible not only to prime T-cells with bcr/abl-specific 
      synthetic peptides, but also to stimulate T-cells directly with Ph-positive DCs. 
      Use of DCs might serve as a novel therapeutic approach in CML patients, due to 
      their ability to induce highly specific T-cell responses in an autologous system.
FAU - Heinzinger, M
AU  - Heinzinger M
AD  - Department of Hematology/Oncology, University Medical Center Freiburg, Germany.
FAU - Waller, C F
AU  - Waller CF
FAU - von den Berg, A
AU  - von den Berg A
FAU - Rosenstiel, A
AU  - Rosenstiel A
FAU - Lange, W
AU  - Lange W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Antigens, CD)
RN  - 0 (Dextrans)
RN  - 0 (HLA-DR Antigens)
RN  - I223NX31W9 (Fluorescein-5-isothiocyanate)
SB  - IM
MH  - Adult
MH  - Antigens, CD/analysis
MH  - Cell Count
MH  - Cell Division
MH  - Dendritic Cells/*cytology/immunology/metabolism
MH  - Dextrans
MH  - Endocytosis
MH  - Female
MH  - Flow Cytometry
MH  - Fluorescein-5-isothiocyanate
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/*pathology
MH  - Lymphocyte Culture Test, Mixed
MH  - Male
MH  - Microscopy, Electron
MH  - Middle Aged
MH  - Phenotype
EDAT- 1999/05/29 00:00
MHDA- 1999/05/29 00:01
CRDT- 1999/05/29 00:00
PHST- 1999/05/29 00:00 [pubmed]
PHST- 1999/05/29 00:01 [medline]
PHST- 1999/05/29 00:00 [entrez]
AID - 10.1007/s002770050497 [doi]
PST - ppublish
SO  - Ann Hematol. 1999 Apr;78(4):181-6. doi: 10.1007/s002770050497.